genome sequencing. Flow cytometry is well equipped in most of the clinical laboratories, is relatively easy to manipulate and is easily accessible. Once the procedure is developed, it enables us to share this method between basic and clinical researchers.
The results on EBV-LCLs further suggest that this method will facilitate the diagnosis of heterozygous carriers. Thus, an advantage of our flow cytometric analysis using ATM phosphorylation also exists in the diagnosis of carriers with missense mutations. It was shown that overexpression of dominantnegative form of misssense mutation at the kinase domain interferes with the ATM autophosphorylation after DNA damage. Further investigation is underway to find whether we can identify the individuals with obligatory heterozygous missense mutation by this assay without EBV transformation.
Flow cytometric analysis enables us to screen simultaneously relatively large numbers of patient samples. We have previously reported that activation of DNA damage checkpoints plays an important role in the prevention of leukemic transformation in myelodysplastic syndrome. Phosphorylation of ATM is detected in refractory anemia with excess blast (RAEB)-II phase but not in RA phase. 7 It is often difficult to morphologically classify these two conditions by microscopy. Measurement of ATM phosphorylation using flow cytometry might help to subclassify myelodysplastic syndrome. Furthermore, acquired mutation of ATM gene is frequently identified in hematological malignancies, such as T-prolymphocytic leukemia, mantle cell lymphoma, B-chronic lymphocytic leukemia. Loss of ATM function shows poorer clinical outcome in B-chronic lymphocytic leukemia. 8 The classification of risk groups using ATM activation may add one of the options for selecting the therapy. As with the other clinical applications, measurement of ATM phosphorylation using flow cytometry may be useful for identification of individuals who may show abnormal response against genotoxic stress such as exposure to radiation or chemotherapeutic agents. If these individuals are screened at the bedside, we can avoid the adverse effect of anticancer drugs by reducing the administration doses. Additionally, this screening method will extend the opportunities for risk assessment of cancer development on the basis of population by identifying heterozygous carriers of the ATM gene in individuals with or without cancer.
Expression of cyclin A in childhood acute lymphoblastic leukemia cells reveals undisturbed G1-S phase transition and passage through the S phase Pediatric acute lymphoblastic leukemia (ALL) is characterized by arrested differentiation of the malignant cell clone with retention of proliferative ability. Earlier we had demonstrated that the majority of leukemic cells reside in the G1 phase of the cell cycle, with a minor proportion of cells in the S and G2 phases and only a few cells in the true G0 phase. 1 Although the majority of ALL cells reside in the G1 phase of the cell cycle, attempts to induce differentiation in vivo or in vitro have not been successful.
In view of this arrested differentiation, we became interested in the distribution of ALL cells within the G1 phase relative to the restriction (R) point. The R point determines whether a cell is committed to proliferation or retains the ability to differentiate. 2 Progression through the R point is regulated by the functional inactivation of the retinoblastoma protein (pRb) through a complex stepwise process that includes a sequential phosphorylation by at least two different cyclin-dependent kinase (cdk) complexes, cyclin D/cdk4,6 and cyclin E/cdk2 inducing a loss of nuclear tethering and the activation of E2F transcriptional programs that permit G1-S phase transition. 3 In pediatric ALL cell samples, both cyclin D/cdk4,6 and cyclin E/cdk2 kinase complexes were active; correspondingly, pRb was phosphorylated at both the cyclin D/cdk4,6-and cyclin E/cdk2-specific sites. 4 Hyperphosphorylation of pRb by cyclin D/cdk4,6 and cyclin E/cdk2 kinase complexes indicated that the ALL cells were beyond the R point at the initiation of the S phase. 4 However, the observed small percentage of S-phase cells in ALL did not support this assumption. In addition, whereas a significant amount of pRb in ALL cells had lost nuclear tethering, 4 a fraction of this soluble pRb was still bound to E2F1, suggesting a repression of E2F1-dependent transcriptional activity (Schmitz NMR et al., unpublished results). In summary, all these findings may be attributed to the partial inactivation of pRb functions in ALL cells resulting in the loss of differentiation, but not yet in a commitment to enter the S phase.
We were interested in assessing the distribution of ALL cells within the G1 phase and the G1-S phase transition in ALL cell populations because cells beyond the R point should be prepared to enter the S phase. The literature points out that cyclin A contributes to the G1-S phase transition and is expressed during the S and G2 phases. 5 This study using immunological techniques shows that an orchestrated expression of cyclin A takes place in ALL cells entering and progressing through the S phase. We conclude that in ALL cells, there is no evidence of a disturbed transition from the late G1 to the S phase. This favors the scenario whereby the majority of ALL cells is not committed to entering the S phase, and therefore would not have passed the R point.
Staining smears of cells from untreated precursor-B cell ALL patients with a monoclonal anti-cyclin A antibody revealed a variable percentage of cells with a positive nuclear reaction. In 35 samples of untreated precursor-B cell ALL cells, 7.0 ± 3.7% (mean±1s.d.) stained positive for cyclin A (range 1.1-17.5%). This was in sharp contrast to staining for cyclin E, which resulted in 96.0±3.3% positive cells. By morphology, cyclin A-positive cells were, on average, larger than cyclin A-negative cells.
Samples from the same ALL patients were stained for Bromodeoxyuridine (BrdU) incorporation with a monoclonal anti-BrdU antibody. The percentage of BrdU-positive S-phase cells was 6.6 ± 3.3 (range 0.8-14.5%). In the 35 ALL samples investigated, Spearman's rank correlation between the BrdU labeling index and the percentage of cyclin A-positive cells was highly significant (r ¼ 0.982; Po0.0001). A regression plot of the 35 ALL samples is shown in Figure 1 . On average, the percentage of cyclin A-positive cells was slightly higher than the percentage of BrdU-positive S-phase cells, because of the expression of cyclin A not only during the S phase but also probably during the G2 phase. On the basis of the close correlation between the two variables, the technically simple assessment of cyclin A expression in ALL cells could be a substitute for the more complex BrdU labeling index. A strong positive correlation between cyclin A RNA or protein expression and the percentage of cells in the S and G2 phases in hematological malignancies has been previously demonstrated. 6 This study shows that this correlation also holds true for cyclin A staining of ALL smears.
To confirm that cyclin A was exclusively expressed in S-and G2-phase cells, flow cytometric analyses were performed. In six ALL cases, cyclin A expression was assessed by flow cytometry as well as by immunocytochemistry. The correlation between the percentages of cyclin A-positive cells determined by the two methods was 0.988 (Po0.001). However, we consistently found the percentage of cyclin A-positive cells in smears to be higher than in flow cytometry, with a mean difference of 2.0 ± 1.9% (range 0.5-5.6%). Flow cytometry confirmed that the majority of cyclin A-positive cells had higher-than-modal DNA content, corresponding to the DNA content of cells in the S and G2 phases (Figure 2 ). However, 2-6% of the total cell population had a DNA content between 2n and 4n, but did not express cyclin A (Figure 2 ), a finding that might have been caused by insufficient permeabilization of cells in suspension for detection of nuclear cyclin A. This interpretation would be supported by the above-mentioned difference in the percentages of cyclin A-positive cells between cell smears and cell suspensions. However, it cannot be completely ruled out that some cyclin Anegative cells with a DNA content greater than 2n could represent cells blocked in the S phase with a loss of cyclin A expression, and considering the strong correlation between cyclin A expression and BrdU incorporation, they could also have disturbed DNA replication.
To verify that BrdU incorporation and cyclin A staining were largely detecting the same cell population, smears from six patients with ALL were simultaneously stained for cyclin A expression and BrdU incorporation. Of all BrdU-positive S-phase cells, 97.2±1.4% (mean±1s.d.) were positive for cyclin A, compared with only 1.1 ± 0.5% of cells expressing cyclin A in the non-S-phase cell population (G0/G1 or G2). Of all cyclin A-positive cells, 10.3 ± 3.2% were not in the S phase, and by morphology corresponded to large blast cells assumed to be in the G2 phase. This assumption was supported by the flow cytometric investigations reported above. The finding that 2.8 ± 1.4% (range 1.2-5.0%) of the S-phase cells lacked cyclin A expression may have resulted from technical difficulties in recognizing faint cyclin A staining against a strong BrdUpositive signal. In contrast we cannot completely exclude the possibility that cells at the G1-S boundary begin to incorporate measurable amounts of BrdU slightly before the cyclin A protein is expressed in detectable quantities.
The simultaneous staining of smears for BrdU incorporation and cyclin A expression could result in interference between the two cytochemical reactions, leading to false-positive or false-negative results. Hence, cytospin smears of the same six patients were stained separately for cyclin A expression (range 3.2-16.4%) and BrdU incorporation (range 2.8-15.7%). On the basis of the assumption that cyclin A expression is restricted to cells in the S and G2 phases, the percentages of S-phase cells (BrdU-positive/cyclin A-positive), G2 cells (BrdU-negative/ cyclin A-positive) and G0/G1 cells (BrdU-negative/cyclin A-negative) could be calculated, as well as the percentages of (Table 1) , confirming the fact that cyclin A is expressed exclusively during the S and G2 phases of the cell cycle, and that double staining has no adverse effect on data readout. The results of this study rely only on the protein expression of cyclin A, and no functional assay to detect cyclin A/cdk2 kinase activity in vitro was performed. However, the tight correlation between cyclin A expression and BrdU incorporation favors the idea that the in vivo kinase activity in cyclin A-expressing cells was functional, as cells lacking this activity could not progress through the S phase. 7 According to the results of this study, there was no evidence of an accumulation of cyclin A-positive cells that are unable to progress through the S phase, and therefore lack BrdU incorporation, or of an accumulation of BrdU-positive cells that could not progress through the S phase because of deficient cyclin A expression.
In conclusion, this study revealed an undisturbed transition of ALL cells from the G1 to the S phase, with only a small percentage of cells triggered to enter the S phase. These findings are difficult to reconcile with an accumulation of ALL cells in the late G1 phase, as suggested from the hyperphosphorylation of pRb. Accordingly, the loss of differentiation is not the result of a commitment to complete the mitotic cycle. Although most pRb is phosphorylated to a degree that induces loss of nuclear tethering in pediatric ALL cells, part of this soluble pRb was still bound to E2F1, a fact that suggested a persistent repression of transcriptional activity. Together, loss of nuclear tethering with retention of the ability to bind E2F1 could reflect a partial inactivation of pRb functions, resulting in loss of differentiation without traversing the R point. This model is in agreement with a recent study demonstrating that the control of the R point occurs by a switching mechanism in the pRb-E2F pathway converting growth stimuli into an all-or-none E2F response. 8 It is possible that interfering with the mechanisms responsible for the partial inactivation of pRb functions in ALL cells could be the starting point for the development of a differentiation-inducing therapy.
Redundant function of retinoic acid receptor isoforms in leukemogenesis unravels a prominent function of genome topology and architecture in the selection of mutagenic events in cancer Retinoic acid receptors (RARs) are members of a much larger group of ligand-dependent transcription factors, the so-called nuclear receptors. In mammals, there are three distinct RAR subtypes: RARa, RARb and RARg. 1 RARs share a high sequence homology, but show distinct transcriptional properties and expression pattern, suggesting similar but not necessarily overlapping functions. In haematopoietic differentiation, for example, the function of RARg is uniquely required to maintain the stem cell compartment, whereas RARa seems to work primarily at later stages, favouring differentiation. 2 In acute promyelocytic leukaemia (APL), chromosomal translocations involve in 100% of cases the a-subtype of the RAR gene (RARa), on chromosome 17. These translocations lead to the synthesis of chimeric proteins: in 95% of the cases, the translocation partner is the PML (promyelocytic leukaemia) gene on chromosome 15, leading to the formation of PML-RARa fusion gene. 3 Both in vitro and in vivo studies have well defined the oncogenic roles of PML-RARa fusion protein in the pathogenesis of APL, acting as an altered RAR. 4 In our previous work, we studied the transcriptional and biological properties of chimeric constructs where PML was fused to RARb or RARg to generate the PML-RARb and PML-RARg fusion proteins (which do not exist in nature). Both chimeric proteins demonstrated similar properties to PML-RARa in vitro. 5 Here, we extended this analysis to determine directly whether PML-RARg (as a test case), like PML-RARa, is able to induce APL.
We used the same approach successfully used to show that PML-RARa can initiate leukaemia in vivo.
6 Murine haematopoietic progenitors (Lin À cells) were transduced with a retroviral vector, which encodes for PML-RARg, together with the green fluorescence protein (GFP). As control, we used Lin À cells infected with the empty vector, which express GFP only. The transduced cells were sorted by cytofluorimetry using the co-expressed GFP as a selection marker. From previous studies, we have observed that the levels of PML-RARg are equivalent to those obtained by transduction of PML-RARa. 5 Immediately
